Sapropterin is the pharmaceutical active moiety corresponding to naturally occurring tetrahydrobiopterin (BH4), an essential cofactor involved in phenylalanine hydroxylation and other hydroxylation reactions. The pharmaceutical product is commonly supplied as sapropterin dihydrochloride, the synthetic dihydrochloride salt of naturally occurring tetrahydrobiopterin. FDA documentation identifies sapropterin dihydrochloride as the active pharmaceutical ingredient in Kuvan.
Sapropterin Dihydrochloride API is used in pharmaceutical formulations for conditions involving elevated phenylalanine concentrations, particularly phenylketonuria (PKU) in responsive patients. It functions as a synthetic form of the naturally occurring cofactor BH4 and can enhance residual phenylalanine hydroxylase activity in appropriate patients.
The exact API form should be specified as Sapropterin Dihydrochloride, rather than simply Sapropterin, because the dihydrochloride salt has a distinct molecular formula, molecular weight and CAS number. PubChem lists CAS 69056-38-8, molecular formula C₉H₁₇Cl₂N₅O₃, and molecular weight 314.17 g/mol for the dihydrochloride substance.
Sapropterin is a tetrahydropterin compound and the active moiety of sapropterin dihydrochloride. The free active moiety has the molecular formula C₉H₁₅N₅O₃ and molecular weight 241.25 g/mol, while the dihydrochloride salt has molecular weight 314.17 g/mol.
FDA describes sapropterin dihydrochloride as a synthetic preparation of the dihydrochloride salt of naturally occurring tetrahydrobiopterin. The API is described as an off-white to light yellow crystalline or crystalline powder.
Sapropterin Dihydrochloride is used in the management of phenylketonuria (PKU) in patients who are responsive to sapropterin therapy. Its pharmaceutical role is associated with increasing the activity of phenylalanine hydroxylase in responsive patients and thereby supporting the conversion of phenylalanine to tyrosine.
Sapropterin is also associated with tetrahydrobiopterin biology, where BH4 functions as a cofactor for several hydroxylation enzymes.
Sapropterin is a synthetic form of the naturally occurring cofactor tetrahydrobiopterin (BH4). Phenylalanine hydroxylase requires BH4 for the conversion of phenylalanine to tyrosine. In patients with residual phenylalanine hydroxylase activity who are responsive to treatment, sapropterin can increase enzymatic activity and reduce blood phenylalanine concentrations.
Quality control of Sapropterin Dihydrochloride API should include appropriate pharmaceutical testing for identity, assay, related substances, water or moisture, residual solvents, inorganic impurities and other applicable quality attributes.
Because public regulatory sources do not establish a single universal numerical API release specification covering every manufacturer and market, numerical limits should be taken from the applicable current pharmacopoeial monograph or approved manufacturer specification rather than being invented.
Manufacturing of Sapropterin Dihydrochloride requires controlled synthesis and salt formation followed by purification, drying and analytical release testing. Because sapropterin contains defined stereochemistry, appropriate stereochemical control is an important part of API manufacturing and characterization.
A pharmaceutical-grade manufacturing process should incorporate validated analytical methods, controlled raw materials, documented batch processing and appropriate impurity controls.
Sapropterin Dihydrochloride has the following verified characteristics:
FDA gives the pharmaceutical salt as C₉H₁₅N₅O₃·2HCl with a molecular weight of 314.17, while PubChem expresses the same salt composition as C₉H₁₇Cl₂N₅O₃.
Sapropterin Dihydrochloride API should be packed in suitable pharmaceutical-grade containers that protect the material from contamination, moisture and environmental exposure. Storage conditions should follow validated stability data and the applicable approved API specification.
Typical documentation for Sapropterin Dihydrochloride API may include:
A qualified Sapropterin API manufacturer should maintain controlled pharmaceutical manufacturing processes, validated analytical testing and comprehensive quality documentation. For this stereochemically defined active ingredient, consistent control of identity, assay, purity and relevant impurities is important for pharmaceutical development and commercial manufacturing.
| Parameter | Specification |
|---|---|
| Appearance | white to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 0.5% |
| Residue on Ignition | NMT 0.1% |
| Individual Impurity | NMT 0.10% |
| Total Impurities | NMT 0.50% |
| Water Content | NMT 1.0% |